Michael Rabenstein

Dr. Michael Rabenstein

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
MRMichael Rabenstein
Michael Rabenstein
FPFranziska Peter
Franziska Peter
SJSarah Joost
Sarah Joost
MTMichaela Trilck
Michaela Trilck
ARArndt Rolfs
Arndt Rolfs
MFMoritz J Frech
Moritz J Frech

1 June 2017 in Data in Brief
Verified
Journal Article
Open access
FPFranziska Peter
Franziska Peter
MTMichaela Trilck
Michaela Trilck
MRMichael Rabenstein
Michael Rabenstein
ARArndt Rolfs
Arndt Rolfs
MFMoritz J Frech
Moritz J Frech
Data presented in this article demonstrate the generation and characterization of two novel Niemann-Pick disease Type C1 (NPC1) patient-specific induced pluripotent stem cell (iPSC) lines, related to the research article Trilck et al. (Diversity of Glycosphingolipid GM2 and Cholesterol Accumulation in NPC1 Patient-Specific iPSC-Derived Neurons; Brain Res.; 2017; 1657:52-61. doi: 10.1016/j.brainres.2016.11.031). For reprogramming fibroblasts, carrying the novel homozygous mutation c.1180T>C and the prevalent homozygous mutation c.3182T>C, were used. Reprogramming into patient-specific iPSCs was induced by retroviral transduction of the transcription factors Sox2, Klf4, Oct4 and c-Myc, and confirmed according to their pluripotency. The iPSCs were subsequently differentiated into neural progenitor cells, which were terminally differentiated into functional neurons and glial cells. The generation of these cell lines provides further valuable tools to investigate pathogenic mechanism of NPC1 in human neuronal cells carrying different NPC1 mutations.

20 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MRMichael Rabenstein
Michael Rabenstein
FPFranziska Peter
Franziska Peter
ARArndt Rolfs
Arndt Rolfs
MFMoritz J Frech
Moritz J Frech
Niemann-Pick disease Type C1 (NPC1) is a rare hereditary neurodegenerative disease. NPC1-patients suffer, amongst others, from ataxia, based on a loss of cerebellar Purkinje cells (PCs). Impaired expression/function of excitatory amino acid transporters (EAATs) are suspected of contributing to PC-degeneration in hereditary spinocerebellar ataxias (SCAs). Thus, we studied EAAT-expression and its impact to PC-activity in NPC1−/–mice. Western blot revealed reduced EAAT1, EAAT2, EAAT4, and βIII-spectrin levels in NPC1−/–mice. EAATs play a crucial role in synaptic transmission, thus we were interested in the impact of the reduced EAAT-expression on the function of PCs. Patch-clamp recordings of PCs showed no differences in the firing patterns of NPC1+/+and NPC1−/–mice using a low internal chloride concentration. Because EAAT4 also comprises a chloride permeable ion pore, we perturbed the chloride homeostasis using a high internal chloride concentration. We observed differences in the firing patterns of NPC1+/+and NPC1−/–mice, suggesting an impact of the altered EAAT4-expression. Additionally, the EAAT-antagonist DL-TBOA acts differently in NPC1+/+and NPC1−/–mice. Our data support the line of evidence that an altered EAAT-expression/function is involved in neurodegeneration of PCs observed in SCAs. Thus, we suggest that similar pathogenic mechanisms contribute the loss of PCs in NPC1.

10 October 2019 in Cerebral Cortex
Verified
Journal Article
Closed access
XFXiao Feng
Xiao Feng
FYFan Yang
Fan Yang
MRMichael Rabenstein
Michael Rabenstein
ZWZhen Wang
Zhen Wang
MFMoritz J Frech
Moritz J Frech
JLJiankai Luo
Jiankai Luo
Niemann–Pick type C1 (NPC1) disease is characterized by neurodegeneration caused by cholesterol accumulation in the late endosome/lysosome. In this study, a defective basal and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-stimulated internalization of GluR2-containing AMPA receptors in NPC1−/− cortical neurons was detected. Our results show that the amount of cholesterol and group I metabotropic glutamate receptors (mGluR1/5) in lipid rafts of NPC1−/− cortical tissue and neurons are decreased and their downstream signals of p-ERK are defective, which are restored by a rebalance of cholesterol homeostasis through β-cyclodextrin (β-CD) treatment. Application of 3,5-dihydroxyphenylglycine (DHPG)—a mGluR1/5 agonist—and β-CD markedly increases the internalization of AMPA receptors and decreases over-influx of calcium in NPC1−/− neurons, respectively. Furthermore, the defective phosphorylated GluR2 and protein kinase C signals are ameliorated by the treatment with DHPG and β-CD, respectively, suggesting an involvement of them in internalization dysfunction. Taken together, our data imply that abnormal internalization of AMPA receptors is a critical mechanism for neuronal dysfunction and the correction of dysfunctional mGluR1/5 is a potential therapeutic strategy for NPC1 disease.

Verified
Journal Article
Open access
PDF file
MRMichael Rabenstein
Michael Rabenstein
NMNico Murr
Nico Murr
Andreas HermannAndreas Hermann
Andreas Hermann
ARArndt Rolfs
Arndt Rolfs
MFMoritz J Frech
Moritz J Frech
Niemann-Pick Disease Type C1 (NPC1) is a rare hereditary neurodegenerative disease belonging to the family of lysosomal storage disorders. NPC1-patients suffer from, amongst other symptoms, ataxia, based on the dysfunction and loss of cerebellar Purkinje cells. Alterations in synaptic transmission are believed to contribute to a pathological mechanism leading to the progressive loss of Purkinje cells observed in NPC1-deficient mice. With regard to inhibitory synaptic transmission, alterations of GABAergic synapses are described but functional data are missing. For this reason, we have examined here the inhibitory GABAergic synaptic transmission of Purkinje cells of NPC1-deficient mice (NPC1−/−). Patch clamp recordings of inhibitory post-synaptic currents (IPSCs) of Purkinje cells revealed an increased frequency of GABAergic IPSCs in NPC1−/− mice. In addition, Purkinje cells of NPC1−/− mice were less amenable for modulation of synaptic transmission via the activation of excitatory NMDA-receptors (NMDA-Rs). Western blot testing disclosed a reduced protein level of phosphorylated alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPA-Rs) subunit GluA2 in the cerebella of NPC1−/− mice, indicating a disturbance in the internalization of GluA2-containing AMPA-Rs. Since this is triggered by the activation of NMDA-Rs, we conclude that a disturbance in the synaptic turnover of AMPA-Rs underlies the defective inhibitory GABAergic synaptic transmission. While these alterations precede obvious signs of neurodegeneration of Purkinje cells, we propose a contribution of synaptic malfunction to the initiation of the loss of Purkinje cells in NPC1. Thus, a prevention of the disturbance of synaptic transmission in early stages of the disease might display a target with which to avert progressive neurodegeneration in NPC1.

1 December 2015 in BioResearch Open Access
Verified
Journal Article
Open access
MFMoritz J Frech
Moritz J Frech
MRMichael Rabenstein
Michael Rabenstein
KBKatja Bovensiepen
Katja Bovensiepen
SRSebastian Rost
Sebastian Rost
ARArndt Rolfs
Arndt Rolfs
Niemann–Pick type C1 disease (NPC1) is a neurodegenerative disorder caused by mutations in the NPC1 gene. Actual, no causative treatment for NPC1 is available, although some drugs have been proven to be beneficial to patients, for example, 2-hydroxypropyl-β-cyclodextrin (CDX). In this study, we used the BALB/c_Nctr-Npc1m1N/-J mouse strain to study the effect of CDX, which is described to prolong the life span and to alleviate the pathogenic phenotype. By means of patch clamp recordings, we measured inhibitory postsynaptic currents (IPSCs) of CA1 pyramidal cells of CDX-treated and -untreated animals to elucidate the influence of CDX on the synaptic transmission. Surprisingly, CDX induced a significantly higher GABAergic IPSC frequency in wild-type mice than in NPC1−/− mice. Although the IPSCs were mainly GABAergic, we observed a significant reduction of the IPSC frequency in the presence of the glycine receptor antagonist strychnine. The effect of strychnine did not differ in untreated and treated animals, indicating that the effect of CDX was most likely not based on an interaction with glycinergic transmission machinery. However, the unexpected effect of CDX on the GABAergic synaptic transmission is of special interest as a disturbance plays, for example, a crucial role in epilepsy and, moreover, as CDX is currently under investigation as a treatment for NPC1 in humans.